Affiliations 

  • 1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
  • 2 Vietnamese Association of Diabetes and Endocrinology, Vietnam
  • 3 Rajavithi Hospital, College of Medicine, Rangsit University, Ministry of Public Health, Bangkok, Thailand
  • 4 Department of Endocrinology, Singapore General Hospital, Singapore
  • 5 Universiti Sains Malaysia,, Health Campus in Kelantan, Kelantan, Malaysia
  • 6 Myanmar Diabetes Association, Yangon, Myanmar
  • 7 Department of Medicine, University of Medicine 2, Yangon, Myanmar
  • 8 BIRDEM Academy, Dhaka, Bangladesh
  • 9 Department of Clinical Medicine, Diabetes Research Unit, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
  • 10 Diabetology Unit, Preah Kossamak Hospital, Phnom Penh, Cambodia
  • 11 Department of Medicine, Calmette Hospital, Phnom Penh, Cambodia
  • 12 Center of Diabetes, Mahosot Hospital, Vientiane, Laos
Indian J Endocrinol Metab, 2017;21(3):478-481.
PMID: 28553609 DOI: 10.4103/ijem.IJEM_82_17

Abstract

Southeast Asia faces a diabetes epidemic, which has created significant challenges for health care. The unique Asian diabetes phenotype, coupled with peculiar lifestyle, diet, and healthcare-seeking behavior, makes it imperative to develop clinical pathways and guidelines which address local needs and requirements. From an insulin-centric viewpoint, the preparations prescribed in such pathways should be effective, safe, well tolerated, nonintrusive, and suitable for the use in multiple clinical situations including initiation and intensification. This brief communication describes the utility of premixed or dual action insulin in such clinical pathways and guidelines.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.